Texte intégral
Decentralized Procedure DK/H/2713/001/DC
History of e-CTD sequences:
September 2016
Sequence Date of
submission DK BE BG DE EE EL ES FR HU LT LU PL PT RO SK NL Submission description Submission
Type Related
Sequence Submission Unit 0000 September
2016 X X X X X X X X X X X X X X X X New application for Marketing Authorization MAA 0000 initial
Documents relatifs
Profile comparison between Travoprost Timolol 0.04mg/ml – 5mg/ml eye drops solution preservative free and DUOTRAV reference products (ALCON) reveals similarity between the
Five clinical studies were conducted for DuoTrav 40 micrograms/mL + 5 mg/mL eye drops, solution (Alcon Laboratories) to support the efficacy and safety of the
A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary
The active components of Travoprost/Timolol Eye Drops, Travoprost and Timolol maleate have each been approved as first line therapeutic agents for the reduction of
Process validation protocol for Travoprost-Timolol/Pharmathen (40 micrograms/mL + 5 mg/ml) preservative free eye drops, solution in multi dose container is enclosed in
[r]
Excipients: Macrogolglycerol hydroxystearate 40, sodium chloride, disodium edetate, sodium dihydrogen phosphate dihydrate, anhydrous disodium phosphate, hydrochloric acid or/and
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN.. Keep out of the sight and reach
